Archive — US — techcrunch
Reed Jobs would rather talk about curing cancer than his last name
Reed Jobs, son of Steve Jobs, focuses on his venture firm Yosemite, which he launched in 2023 to innovate cancer treatments. He promotes a mix of philanthropy and venture capital to create biotech companies. Jobs emphasizes the growing role of AI in drug discovery and oncology, revealing ambitious plans to tackle significant cancer challenges and enhance research through innovative funding strategies.
Key points
- Reed Jobs prefers discussing his work and curing cancer rather than his father, Steve Jobs.
- Yosemite, founded in 2023, focuses exclusively on oncology, aiming to create biotech companies from academic research through a mix of philanthropy and venture funding.
- Jobs highlights an expanding opportunity in cancer treatment due to AI advancements in drug discovery and clinical trials.
- Yosemite has a portfolio of nearly 25 companies and aims to fund innovative cancer treatments, including targeting the often undruggable p53 gene.
- Jobs addresses concerns regarding NIH funding cuts and the varying investment landscape within biotech.
- He promotes democratizing science through AI, stating its role in accelerating drug discovery while advocating for funding and innovation in biotech.
Why it matters
- Yosemite is part of a trend where biotech ventures are increasingly tied to advancements in AI, reflecting a broader industry shift.
- The significant developments in cancer treatment, such as the development of drugs like Lumakras, underline the importance of investing in innovative research.
- The recent focus on longevity and the intersection of multiple biological disciplines showcases an evolving interest in comprehensive healthcare approaches.
Reed Jobs' commitment to innovative cancer solutions through Yosemite illustrates a notable shift in biotech, utilizing advanced AI technologies and unique funding strategies, aiming to make impactful contributions to oncology.